| September 4 |
ViaCell Announces ViaCyte Collaboration with EMD Serono, Inc. |
| September 4 |
Positive Bioequivalence Study Results Trigger Milestone Payment for
Eurand |
| September 4 |
InterMune Announces Approval of Clinical Trial Authorization for
Phase 1b Trial of ITMN-191 |
| September 4 |
AstraZeneca Enhances Clinical Research Capabilities in China With
First Clinical Pharmacology Unit |
| September 4 |
Pharmexa Loses European Patent Appeal for Broad Claims to
Telomerase-Based Cancer Vaccines |
| September 4 |
Shire Voluntarily Withdraws a Limited Portion of Daytrana
(Methylphenidate Transdermal System) Patches |
| September 4 |
Omnicom Acquires Leading Healthcare Marketing Communications Firm
in China |
| September 4 |
Noven Provides Update on Daytrana Methylphenidate Transdermal
System |
| September 4 |
Canon Communications Acquires Engel Publishing Partners from
Euromoney Institutional Investor PLC, Expanding Its Market Reach to
Global Pharmaceutical Manufacturing Sector |
| September 5 |
Lundbeck and Takeda Form Alliance to Develop and Commercialize a
Portfolio of Novel Compounds in the US and Japan for the Treatment
of Mood and Anxiety Disorders |
| September 5 |
Ventana Medical Systems Acquires Spring BioScience |
| September 5 |
Bayer Intends to Delist from the New York Stock Exchange |
| September 5 |
Thermo Fisher Scientific Acquires Instrument Sales Business of
Davis Inotek |
| September 5 |
Public Communication - Health Canada Endorsed Important Safety
Information on Ketek(telithromycin) |
| September 5 |
Colorcon Acquires Pharmaceutical Excipients and Coating Division of
Chr. Hansen, Inc. |
| September 5 |
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro
Patent Decision |
| September 5 |
Teva Receives Favorable Court Decision Regarding Generic Famvir
Tablets; Novartis' Motion for Preliminary Injunction Denied |
| September 6 |
AstraZeneca Launches and Prices a $6.9 Billion Bond Issue |
| September 6 |
FDA Approves First Generic Versions of Coreg |
| September 6 |
Pfizer Oncology Initiates Global Phase III Trial to Evaluate
Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell
Lung Cancer |
| September 6 |
China Aoxing Pharmaceutical Company Receives Government Approval
for Increased Ownership of its Main Operating Subsidiary, Hebei
Aoxing; Amends Terms of the Acquisition Agreement |
| September 6 |
American Oriental Bioengineering Completes Acquisition of Changchun
Xinan Pharmaceutical Group Company Ltd. |
| September 6 |
Biogen Idec Announces Strategic Updates at Investor Meetings |
| September 6 |
Elliott 'Extremely Dissatisfied' With Genzyme Bid for Bioenvision;
Believes Offer Significantly Undervalues Company |
| September 6 |
Youth Drug Use at a Five Year Low, New Survey Shows |
| September 6 |
New Jersey High Court Denies Nationwide Class-Action Status to
Insurance Companies Seeking Vioxx Reimbursements |
| September 6 |
CDC Report Shows Largest One-Year Increase in Youth Suicide Rate in
15 Years |
| September 7 |
Wyeth and Nycomed Announce Court Denial of Preliminary Injunction |
| September 7 |
Theravance Retains Full Ownership of Gastrointestinal Motility
Dysfunction Program and TD-1792 Antibiotic |
| September 7 |
Ablynx and Boehringer Ingelheim Announce Major Global Strategic
Alliance to Discover, Develop and Commercialize Novel Nanobody
Therapeutics |
| September 7 |
Sens. Grassley, Kohl Say Public Should Know When Pharmaceutical
Makers Give Money to Doctors |
| September 7 |
Enzo Biochem, Inc. Files Appeal to Federal Court Decision |
| September 7 |
Publicis Groupe Announces Intention to Delist its American
Depository Receipts (ADRs) from the New York Stock Exchange and to
Deregister and Terminate its Reporting Obligations under the U.S.
Securities Laws |
| September 7 |
Pozen/AstraZeneca Announce Start of the PN 400 Phase III Program |
| September 7 |
Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to
Discover, Develop, and Commercialize microRNA Therapeutics |
| September 7 |
Novartis to Defend Its Intellectual Property Rights for Famvir
Despite an "at-risk" Generic Launch in US |
| September 7 |
Statement of Eli Lilly and Company on Dr. David Egilman Settlement: |
| September 7 |
This Week, Pharma Bloggers Criticize Merck’s Vioxx Studies,
Pfizer’s Third Breach of Confidential Data, and the Bush
Administration |
| September 10 |
Palatin Technologies Announces Reacquisition of Full Rights to
Bremelanotide Program |
| September 10 |
MedImmune Resolves FDA Observations Regarding Manufacturing Process
for FluMist |
| September 10 |
BioVascular, Inc. Merges with Revitus and Acquires First-In-Class
Platelet Count Reducer |
| September 10 |
Repligen Announces Settlement with ImClone In Erbitux Lawsuit |
| September 10 |
United BioSource Acquires Interest in Leading Adaptive Design
Technology Service Provider |
| September 10 |
Sanofi-aventis Announces Settlement of Average Wholesale Price
Civil Suits With the U.S. Department of Justice Relating to Anzemet |
| September 10 |
$52.5 Million Settlement Against Sepracor Inc. Approved |
| September 10 |
Pfizer Issues a Dear Healthcare Professional Letter to Inform
Healthcare Professionals of the Presence of Ethyl Methanesulfonate
in Viracept |
| September 10 |
Statement by Commissioner von Eschenbach on the Release of the
Strategic Framework Document on Import Safety |
| September 11 |
Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest
AG |
| September 11 |
Evotec Sells its Chemical Development Business to Aptuit for GBP
31.5m (approx. EUR 46.4m; US$ 63.9m) in Cash |
| September 11 |
Alcon Waives Minimum Acceptance Condition for WaveLight AG |
| September 11 |
Biovail Says Settlement With Maris, BAS Expected to Be Helpful in
Suit Against Hedge Funds and Others |
| September 11 |
Merck & Co., Inc. Announces Completion of NovaCardia, Inc.
Acquisition |
| September 11 |
Aptuit to Acquire CPD Business of Evotec AG |
| September 11 |
Vote for the Most Admired Pharmaceutical, Biotechnology, and
Specialty Companies |
| September 11 |
Adverse Drug Events Reported to FDA Appear to Have Increased
Markedly |
| September 11 |
FDA - MedWatch - Rocephin (ceftriaxone sodium) - Dear Healthcare
Provider Letter Clarifying Potential Risk Associated With
Concomitant Use Of Rocephin With Calcium Containing Products |
| September 11 |
GlaxoSmithKline Responds to JAMA Articles |
| September 12 |
Former Banc of America Securities Analyst David Maris Comments on
Decision by Biovail to Drop Its Claims Against Him; Denies That He
is Cooperating With Biovail |
| September 12 |
FDA Advisory Panel to Review Medtronic's Endeavor Drug Eluting
Stent on October 10 |
| September 12 |
Publicis Groupe Acquires Wcube, France’s Top Independent
Digital Agency |
| September 12 |
Flamel Technologies Announces Medusa License Agreement with Wyeth
Pharmaceuticals |
| September 12 |
Palatin Technologies Refutes Competitive Technologies Contention of
Material Breach |
| September 13 |
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the
Discovery, Development and Commercialization of Antisense Drugs to
Treat Metabolic Diseases |
| September 13 |
Angiotech Receives Favourable Patent Decision from New Zealand's
Intellectual Property Office |
| September 13 |
First Consulting Group (FCG) Announces Sale of FirstGateways
Business to MedPlus, Inc. |
| September 13 |
FDA To Continue Its Review of Requests for Release of Clinical Hold
on Alvimopan (Entereg) |
| September 13 |
FDA Advisory Committees Recommend Continued U.S. Marketing
Authorization for Trasylol |
| September 13 |
New Licence for Cubicin (daptomycin), the First in a Novel Class of
Antibiotic, is Announced Today for the Treatment of Serious
Bloodstream and Heart Infections Caused by the Most Problematic UK
Organisms, Including MRSA |
| September 13 |
Canadian Court Finds Infringement of Lipitor Crystal Form Patent |
| September 13 |
IFRS Information - First Half of 2007 |
| September 13 |
Physicians Urge Kennedy, Dodd to Support Curb on Financial
Conflicts of Interest on FDA Advisory Committees |
| September 13 |
Cephalon Reinforces Important Prescribing and Dosing Information
for Fentora |
| September 14 |
Novartis Completes Agreement with Bayer Schering Related to
Betaseron Rights and Manufacturing |
| September 14 |
Sanofi-aventis Initiates Research Collaboration in China in the
Cancer Stem-Cell Field |
| September 14 |
Bayer Completes Acquisition of U.S. Biologics Manufacturing
Facility from Novartis |
| September 14 |
Bayer Completes Acquisition of U.S. Biologics Manufacturing
Facility from Novartis |
| September 14 |
Four Leading Independent Proxy Advisory Firms Recommend Bausch
& Lomb Shareholders Vote ''For'' Transaction with Warburg
Pincus |
| September 17 |
Sanofi- aventis: A Promising R&D Portfolio, Well Positioned to
Deliver Future Growth |
| September 17 |
FDA Approves Levaquin Short-Course Therapy for Treatment of
Complicated Urinary Tract Infections and Acute Pyelonephritis |
| September 17 |
Depomed Announces Reduction in Force |
| September 17 |
AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart
Risks With ADHD Medications |
| September 17 |
AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart
Risks With ADHD Medications |
| September 17 |
United BioSource Acquires Caro Research, Leader in Simulation
Modeling |
| September 17 |
LabPas CT Selected by Qualia Clinical Services for Phase I Clinical
Trials |
| September 18 |
FDA Clears Genetic Lab Test for Warfarin Sensitivity |
| September 18 |
FDA Alerts Healthcare Professionals to Deaths Linked to Haloperidol |
| September 18 |
FDA - MedWatch - Haloperidol Marketed As Haldol, Haldol Decanoate,
And Haldol Lactate Get New Warnings And Revised Prescription
Information |
| September 18 |
Pharmaceutical Marketers to Spend $2.2 Billion Online in 2011 |
| September 18 |
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec
to Develop Anti-CD103 Therapies |
| September 18 |
GlaxoSmithKline Awarded U.S. Department of Defense Contract to
Pursue Novel Antibacterial Research Program |
| September 18 |
Roche Announces Tamiflu Will be in Ample Supply for 2007-2008 Flu
Season |
| September 18 |
Merck & Co., Inc. Response to Today's New York Medicaid Suit |
| September 18 |
N.Y. AG Cuomo, Mayor Bloomberg Sue Maker of Vioxx for Hiding
Drug’s Risks |
| September 19 |
Bavarian Nordic Strengthens its Commercial Organisation and Updates
on Pipeline Progress |
| September 19 |
Esprit Pharma, Inc. to Be Aquired by Allergan, Inc. |
| September 19 |
NJAG Milgram Announces Task Force to Study the Influence of
Gift-Giving to Physicians by Pharmaceutical Manufacturers, Medical
Device Makers |
| September 19 |
Orexigen Announces Settlement Agreement with Eisai |
| September 19 |
Alnylam Announces the Termination of its Collaboration with Merck
& Co., Inc. |
| September 19 |
Baby Boomers Want Control of Their Own Health and Actively Seek out
Information from Multiple Sources to Help Make Decisions |
| September 20 |
Ventana Responds to Third Extension of Roche's Unsolicited Tender
Offer |
| September 20 |
Sanofi pasteur First Manufacturer to Ship Doses of Influenza
Vaccine for the 2007-2008 Season |
| September 20 |
Roche Extends Tender Offer for Ventana |
| September 20 |
Karo Bio Development of Clinical Candidate LXR-623 Discontinued |
| September 20 |
PSI Brings its Pioneering Efforts to a Close |
| September 20 |
New Survey Finds Strong Public Interest in Prescription Drug Safety
Issues |
| September 21 |
European License for Roche HIV Drug Viracept Recommended for
Reinstatement |
| September 21 |
FDA Sends Kunshan Chemical & Pharmaceutical Company Letter
About its Facilities |
| September 21 |
Statement by FDA Commissioner Andrew C. von Eschenbach on Passage
of FDA Amendments Act of 2007 (FDAAA) |
| September 21 |
Exelixis Research Collaboration With Bristol-Myers Squibb Extended |
| September 21 |
Bausch & Lomb Shareholders Approve Merger with Affiliates of
Warburg Pincus |
| September 21 |
Court Rules for Pfizer in Patent Infringement Case on Neurontin |
| September 21 |
Vaccination and Enrollment Are Discontinued in Phase II Trials of
Merck's Investigational HIV Vaccine Candidate |
| September 21 |
Biomax Informatics AG Acquires Data Mining Business from eudaptics
software gmbh |
| September 24 |
Teva Provides Update On Generic Neurontin Litigation |
| September 24 |
Biogen Idec Announces Research Collaboration with Johns Hopkins
Brain Science Institute |
| September 24 |
Bristol-Myers Squibb to Acquire Adnexus Therapeutics |
| September 24 |
Elixir Pharmaceuticals Files Registration Statement for Proposed
Initial Public Offering |
| September 24 |
US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver
Cancer |
| September 24 |
Dyadic Announces Termination of Employment of its President and
CEO, Mark A. Emalfarb |
| September 24 |
Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma
Development Programs to AstraZeneca |
| September 24 |
MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline
for Use in Influenza Vaccine Development and Production |
| September 24 |
New Brunswick Scientific Completes Merger Transaction with
Eppendorf |
| September 25 |
Pharmacopeia Earns Milestone Payment From Schering-Plough on
Initiation of Phase 1 Clinical Trials of Novel Therapeutic
Candidate |
| September 25 |
GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for
Access to GeneGo Software Suite and Databases |
| September 25 |
Aranesp DAHANCA 10 Study Results Presented at ECCO Annual Meeting |
| September 25 |
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics
Discovery Collaboration for Alzheimer's Disease |
| September 25 |
Panacos Announces Management Changes |
| September 25 |
Impact of discontinuation of Merck HIV study on Crucell's prospects |
| September 25 |
Emisphere Technologies, Inc. and Eli Lilly and Company Settle
Ongoing Litigation |
| September 25 |
Barr Confirms Patent Challenge of Uroxatral |
| September 26 |
Palatin Technologies Announces Reduction of Workforce |
| September 26 |
Depression Intervention in Workplace Increases Employee
Productivity 2.6 Hours a Week |
| September 26 |
Johnson & Johnson Tops Annual Pharmaceutical Company Rankings
in a New Report From Industry-Leading Publication Scrip |
| September 26 |
Verispan's Vector One: Antidepressant Prescribing Decreases in
Teenagers |
| September 26 |
Exclusive Agreement Announced Between Quidel Corporation and Roche
Pharma AG |
| September 26 |
FDA Warns of Potential Serious Side Effects with Breakthrough
Cancer Pain Drug |
| September 27 |
FDA, Leading Pharma Companies Launch Global Collaboration to
Research Genetic Markers Linked to Drug Safety |
| September 27 |
PAREXEL International Completes Acquisition of APEX International
Clinical Research Co., Ltd. |
| September 27 |
Amgen Receives Proposal for Amending EU Prescribing Information for
Aranesp |
| September 27 |
Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per
Outstanding Share |
| September 27 |
Taisho and BrainCells Signed a License Agreement for Taisho's New
Drug Candidates of CNS Indications |
| September 27 |
PhRMA Statement on Enactment of FDA Legislation |
| September 27 |
Wyeth Announces Election of Bernard Poussot as CEO of Company
Effective January 1, 2008 |
| September 28 |
Simcere Pharmaceutical Group Acquires a 51% Stake in Boda
Pharmaceutical Co., Ltd. |
| September 28 |
Celera Announces Clinical Milestone Payment from Merck |
| September 28 |
Novartis and Massachusetts Institute of Technology in New
Partnership Aimed at Transforming Pharmaceutical Manufacturing |
| September 28 |
Eisai Announces Establishment of New Pharmaceutical Marketing
Subsidiary in Belgium |
| September 28 |
Alcon Gains 76.9 Percent of WaveLight Shares and Will Move Forward
with Acquisition |
| September 28 |
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV
and HIV Programs |
| September 28 |
OIG Releases Report of FDA’s Oversight of Clinical Trials,
Concludes Improvement of Information Systems and Processes is
Needed |
| September 28 |
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed
Federal Investigation into Pricing, Sales and Marketing Practices |
| September 28 |
Canadian Federal Court Upholds Viagra Patent |
| September 28 |
FDA Takes Action to Stop Marketing of Unapproved Hydrocodone
Products |
| September 28 |
Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug
Droperidol Unnecessary |
| September 28 |
FDA-MedWatch -Gadolinum Based Contrast Agents: Dear Healthcare
Professional Letter Issued Regarding Boxed Warning And Revisions to
Warning Section of Prescribing Information |
